Pharmaceuticals, Biotechnology and Life Sciences
Noxxon has enroleld and traeted the first patient with newly diagnosed brain cancer in the middle dose cohort of the phase 1/2 clinical trial.
BERLIN–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) a biotechnology company focused on improving cancer treatments by targeting…
Noxxon Pharma said Friday that recruitment of patients in second cohort has been initiated for the middle dose cohort for the Phase 1/2 NOX-A12 plus radiotherapy brain cancer trial.
BERLIN–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by…
NOXXON said Wednesday it has enrolled the first patient in phase 1/2 trial in a therapy of increasing doses of…
Noxxon will present latest Clinical data from phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress on Monday at 09.00 A.M., which shows that the combination of NOX-A12 and pembrolizumab induced an immune response, stable disease in 25% of patients and prolonged time on treatment vs. prior therapy for 35% of patients.
NOXXON Pharma, a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, has treated first patients in its Phase 1/2 clinical trial in patients with metastatic colorectal and pancreatic cancer at the National Center for Tumor Diseases in Heidelberg, Germany.
NOXXON Pharma N.V. has announced a collaboration with Merck & Co. (MSD), Inc, under which the two companies will collaborate…
NOXXON Pharma N.V. a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announced that it presented data yesterday at the ESMO conference in Copenhagen, Denmark, studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment.